# US 2021/0267870 A1 · Compositions that protect cells from oxidative and mitochondrial stress

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0267870 A1
- Document ID: US20210267870A1
- Status: Published application
- Kind: A1
- Application number: 17/258,258
- Filed: 2019-07-10
- Published: 2021-09-02
- Earliest claimed: 2018-07-10
- Assignees: Nuchido Limited
- Applicants: Nuchido Limited
- Inventors: Nichola Jane Conlon; Malcolm Philip Young
- Web page: https://patentgrep.com/patent/US20210267870A1

## CPC

- A61K 8/675: {Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde (tocopheryl nicotinate A61K8/678)}
- A61K 8/27: Zinc; Compounds thereof
- A61K 8/498: {having 6-membered rings or their condensed derivatives, e.g. coumarin}
- A61K 8/4986: {with sulfur as the only hetero atom}
- A61K 8/676: {Ascorbic acid, i.e. vitamin C}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/455: Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A61K 33/30: Zinc; Compounds thereof
- A61Q 19/00: Preparations for care of the skin
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/92: Oral administration
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

There are described compositions comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACT1 peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (Na AD), nicotinic acid mononucleotide (Na MN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof).

## Claims

### Claim 1

A composition comprising an effective amount of a combination of two or more components, said components selected from acacetin, ACT1 peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof); and derivatives thereof and any combination thereof.

### Claim at position 2

2-28. (canceled)

### Claim 29

A method of enhancing cell resistance to DNA damage, oxidative stress, mitochondrial dysfunction, or improving DNA repair capacity, said method comprising the administration of an effective amount of a composition comprising an effective amount of one or more components, said components selected from acacetin, ACT1 peptide, alpha-lipolic acid, alprostadil, anisomycin, apigenin, ascorbic acid, astragalus, berberine, β-lapachone, β-hydroxy-beta-methyl-butyrate, Bacopa monnieri, catechin, catechol, chamomile, chrysin, coumestrol, curcumin, dinitrophenol, dinoprost, ellagic acid, (−)-epigallocatechin gallate, green tea extract, fisetin, genistein, ginsenoside RE, glabridin, 18-α-glycyrrhetinic acid, 18-β-glycyrrhetinic acid, glycyrrhizin, hydroquinone, isoquercitrin (EMIQ), kaempferol, kuromanin, leucine, lithium, luteolin, luteolin, luteolinidin, melatonin, menadione, 1-methylnicotinamide (MNA), methyl salicylate, myricetin, nadide, niacin (vitamin B3), nicotinamide (NAM), nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), nicotinic acid adenine dinucleotide (NaAD), nicotinic acid mononucleotide (NaMN), parsley (Petroselinium crispum), phenylephrine, pokeweed mitogen, 15-Δ prostaglandin J2, puromycin, quercetin, quinolinic acid, retinoic acid, trichostatin A, troxrutin, rutin, tryptophan, vitamin D3, withaferin A, wortmannin and zinc (including salts thereof); and derivatives thereof and any combination thereof.

### Claim 30 (depends on 29)

A method according to claim 29 for use in enhancing cell resistance to DNA damage.

### Claim 31 (depends on 29)

A method according to claim 29 for use in enhancing cell resistance to oxidative stress.

### Claim 32 (depends on 29)

A method according to claim 29 for use in enhancing cell resistance to mitochondrial dysfunction.

### Claim 33 (depends on 29)

A method according to claim 29 for use in improving a cell's DNA repair capacity.

### Claim 34 (depends on 29)

A method according to claim 29 wherein the method comprises enhancing cell resistance to DNA damage, oxidative stress, mitochondrial dysfunction, and improving DNA repair capacity.

### Claim 35 (depends on 29)

A method according to claim 29 wherein the amount of the active component administered in the method is from about 1 mg to about 1000 mg.

### Claim 36 (depends on 29)

A method according to claim 29 wherein the method comprises the mitigation, alleviation or improvement of the effects of ageing in a host.

### Claim 37 (depends on 36)

A method according to claim 36 wherein the method of mitigation, alleviation or improvement of the effects of ageing in a host is by improving a cell's resistance to DNA damage and/or enhancing the cell's DNA repair capacity.

### Claim 38

(canceled)

### Claim 39 (depends on 29)

A method according to claim 29 wherein the daily dosage of the composition is from about 0.1 to about 500 mg/kg body weight.

### Claim 40

(canceled)

### Claim 41 (depends on 36)

A method according to claim 36 wherein the effects of ageing include age related skin conditions, skin conditions related to sun exposure, skin conditions related to pollution exposure, skin conditions related to oxidative stress, and skin conditions related to lifestyle choices, such as diet, alcohol and/or smoking.

### Claim 42 (depends on 36)

A method according to claim 36 wherein the effects of ageing include skin conditions related to inflammatory skin disorders and skin conditions related autoimmune disease skin disorders.

### Claim at position 17

43-44. (canceled)

### Claim 45 (depends on 42)

A method according to claim 42 wherein the skin condition is an age related skin condition.

### Claim 46 (depends on 45)

A method according to claim 45 wherein the age related skin condition includes one or more of sagging, wrinkles, skin elasticity, skin ageing, skin moisture, wounds, acne, skin darkening, skin whitening, pigmentation, age-spots, loss of radiance, puffiness, uneven skin tone, redness, rosacea, loss of barrier function, loss of skin resilience, loss of firmness, stretch-marks, cellulite and dryness.

### Claim 47 (depends on 45)

A method according to claim 45 wherein the skin condition is caused by sun exposure.

### Claim 48 (depends on 45)

A method according to claim 45 wherein the skin condition includes one or more of actinic keratoses, freckles, lentigines or age spots, moles, photosensitivity, polymorphous light eruption, seborrheic keratoses, skin cancer (such as melanoma, squamous cell carcinoma, basal cell carcinoma), solar elastosis or wrinkles and sun burn.

### Claim 49 (depends on 42)

A method according to claim 42 wherein the skin condition is caused by inflammation.

### Claim 50 (depends on 42)

A method according to claim 42 wherein the skin condition includes one or more of acne, asteatotic eczema, atopic dermatitis, contact dermatitis, discoid eczema, eczematous drug eruptions, erythema multiforme, erythroderma, gravitational/varicose eczema, hand eczema, keratosis lichenoides chronica, lichen nitidus, lichen planus, lichen simplex, lichen striatus, mycosis fungoides, pityriasis lichenoides, psoriasis, seborrheic dermatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis and vasculitis.

### Claim 51 (depends on 42)

A method according to claim 42 wherein the skin condition is caused by an autoimmune disease.

### Claim at position 25

52-54. (canceled)

### Claim 55 (depends on 29)

A method according to claim 29 for topical, transdermal, oral or parenteral administration.

### Claim 56 (depends on 55)

A method according to claim 55 for topical administration.

### Claim 57 (depends on 56)

A method according to claim 56 in the form of an aqueous solution, suspension, serum, ointment, cream, gel, sprayable formulation, transdermal patch or bandage.

### Claim at position 29

58-60. (canceled)

### Claim 61 (depends on 55)

A method according to claim 55 for parenteral administration.

### Claim 62 (depends on 61)

A method according to claim 61 for parenteral administration in the form of an intramuscular, intravenous, subcutaneous, intraperitoneal, local or transdermal injections.

### Claim 63 (depends on 55)

A method according to claim 55 for transdermal administration.

### Claim 64 (depends on 63)

A method according to claim 63 in the form of an aqueous solution, suspension, ointment, cream, gel, sprayable formulation, transdermal patch or bandage.

### Claim 65

(canceled)
